SCHEMBL3756003

SCHEMBL3756003

CCCN(CCc1ccc(OC(C)(C)C(=O)O)cc1)S(=O)(=O)c1sc2ccc(Cl)cc2c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 9/20 0.41
PPARD Q03181 4/20 0.41
PPARG P37231 4/20 0.41
ALDH1A1 P00352 1/20 0.41
FABP2 P12104 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PFKFB3 Q16875 5/20 0.40
PFKFB4 Q16877 4/20 0.40
CMA1 P23946 4/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR6 P50406 1/20 0.39
PTPN7 P35236 1/20 0.38
DUSP3 P51452 1/20 0.38
PTPN12 Q05209 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3691319 0.96 PPARA (0.42) PPARAPPARDPPARGALDH1A1FABP2
SCHEMBL13508518 0.91 PPARA (0.43) PPARAPPARDPPARGPTPN7DUSP3
SCHEMBL13508526 0.91 PPARA (0.40) PPARAPPARDPPARGALDH1A1FABP2
SCHEMBL13508550 0.88 PTPN7 (0.45) PPARAPPARDPPARGPTPN7DUSP3
SCHEMBL3680701 0.88 PPARA (0.46) PPARAPPARGPFKFB3PFKFB4CMA1
SCHEMBL3685544 0.87 PPARA (0.43) PPARAPPARDPPARGPTPN7DUSP3
SCHEMBL3685095 0.87 PPARA (0.49) PPARAPPARDPPARGPFKFB3PFKFB4
SCHEMBL3683343 0.87 PPARA (0.41) PPARAPPARDPPARGALDH1A1FABP2
SCHEMBL3690033 0.86 PPARA (0.51) PPARAPPARDPPARGCMA1PTPN7
SCHEMBL3679313 0.85 PFKFB3 (0.43) PFKFB3PFKFB4CMA1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US claimed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US claimed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG PPARA 2/4885PPARD 1/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.